

Special Issue

Clinical Research on Thoracic Cancer

Message from the Guest Editors

Clinical research has come to play an increasingly important role in all malignant diseases, including thoracic cancer. In the last 20 years, molecular biological techniques have proven that cancer is caused by an accumulation of genetic abnormalities; in other words, cancer has come to be considered a type of genetic disease. Precision medicine is a new medical concept in which treatment takes into account individual differences in genetic information, and genomic testing has been shown to be useful as a predictor of cancer treatment.

The advent of immunotherapy and molecular target drugs has significantly changed the treatment scheme for patients with thoracic cancers. In recent years, the introduction of these drugs into the perioperative period has become a hot topic even in the field of thoracic cancer, and some indications of treatment for thoracic cancer have changed significantly. Here, the purpose of this Special Issue is to understand the results of the latest clinical research to provide exciting changes for treatment strategies in thoracic cancer.

Guest Editors

Dr. Yuichi Saito

Department of Thoracic Surgery, Faculty of Medicine, Teikyo University School of Medicine, Tokyo 173-8605, Japan

Dr. Hiroyuki Adachi

Division of Thoracic Surgery, Department of Surgery, Yokohama City University, Yokohama 236-0004, Japan

Deadline for manuscript submissions

6 December 2025



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/215029

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)